Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07349329
PHASE3
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
View on ClinicalTrials.gov
Summary
This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
380
Start Date
2026-03-09
Completion Date
2029-02-21
Last Updated
2026-01-16
Healthy Volunteers
No
Interventions
DRUG
608
608 subcutaneous (SC) injection.
DRUG
Placebo
Placebo subcutaneous (SC) injection.
Locations (1)
Site 01
Beijing, China